Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development: Proceedings of the Twenty-Second Annual Cancer Symposium Detroit, Michigan, USA — April 26–28, 1990

Передня обкладинка
Frederick A. Valeriote, Thomas H. Corbett, Laurence H. Baker
Springer Science & Business Media, 31 бер. 1992 р. - 409 стор.
The focus of the 22nd Annual Detroit Cancer Symposium was the presentation and discussion of cytotoxic agents, with a significant portion of the symposium including the exciting frontiers of drug discovery being explored by the National Cooperative Drug Discovery Groups (NCDDG) Program. The symposium brought together a large number of investigators from government, universities and pharmaceutical companies involved in the discovery and development of new anticancer agents. Exciting new leads were presented and the status of others presently under development was discussed.
Of particular significance has been the initiation of renewed efforts in the area of natural product drug discovery, where the discovery of new cytotoxics is very promising at the moment. A number of major changes have occurred during the last decade in research on drug discovery of cytotoxic agents. Critical reviews of a number of the models and concepts underlying drug discovery represented a continuous thread throughout the meeting, being constantly discussed in terms of their advantages, disadvantages and capabilities of discovering solid tumor active anticancer agents.
A recent development which is to be much applauded and which portends to great discoveries is the new relationship formed between Government, University of Industry. The NCDDG mechanism which stimulates this interaction is an inexpensive manner to greatly magnify the drug discovery and development effort nationally. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development represents a forum which will become the major mode for bringing together these three different components in the equation to regularly discuss new results and ideas.
 

Зміст

DRUG DISCOVERY 1990
v
DATA DISPLAY AND ANALYSIS STRATEGIES FOR THE NCI DISEASEORIENTED IN VITRO ANTITUMOR DRUG SCREEN
xv
DISCOVERY OF SOLID TUMOR ACTIVE AGENTS USING A SOFTAGARCOLONY FORMATION DISKDIFFUSIONASSAY
21
THYMIDYLATE SYNTHASE INHIBITION OF MODIFIED QUINAZOLINE ANTIFOLATES
75
DNAMINOR GROOVE BINDING ANTICANCER AGENTS
91
ZARYLMETHYLAMINO13PROPANEDIOLS AMAPS DISCOVERY SELECTION AND DEVELOPMENT OF FOUR CLINICAL CANDIDATES
109
MECHANISMBASED APPROACHES TO CANCER DRUG DISCOVERY
135
DISCOVERY AND BULK PRODUCTION OF NATURAL PRODUCTS WITH ANTICANCER ACTIVITY THE ROLE OF CHEMICAL ECOLOGY
145
EXTRACHROMOSOMAL DNA AS A TARGET FOR DRUG DEVELOPMENT
211
PROSPECTIVE EVALUATION OF A PREDICTIVE MODEL FOR PLASMA CON CENTRATIONVERSUSTIME PROFILES OF INVESTIGATION...
223
AGENTDIRECTED PRECLINICAL TOXICOLOGY FOR NEW ANTINFOPLASTIC DRUGS
233
PRECLINICAL STUDIES WITH BREQUINAR SODIUM A NOVEL ANTICANCER AGENT
247
DIPHTHERIA TOXINRELATED PEPTIDE HORMONE FUSION PROTEINS NEW TOXINS WITH THERAPEUTIC POTENTIAL
267
ANTIGROWTH FACTOR RECEPTOR ANTIBODIES AS THERAPY FOR CANCER
289
REGULATION OF POLYAMINE BIOSYNTHETIC ACTIVITY AND HOMEOSTASIS AS A NOVEL ANTIPROLIFERATIVE STRATEGY
311
ESPERAMICIN A BMY28175 A NOVEL POTENT ANTITUMOR AGENT OF THE DIYNEENE CLASS
331

CHEMICAL APPROACHES TO IMPROVED RADIOTHERAPY
165
LARGE SCALE ANTICANCER DRUG SCREENING AT STERLING DRUG INC
183
ARE ANTISENSE OLIGONUCLEOTIDES THERAPEUTIC AGENTS OF THE FUTURE?
191
SUPERCOMPUTER AIDED DRUG DESIGN APPLICATION IN ONCOLOGY AND AIDS
201
MODIFIED 2TUMOR L1210 COLON 38 ASSAY TO SCREEN FOR SOLID TUMOR SELECTIVE AGENTS
345
5FLUOROURACIL SCHEDULE OPTIMIZATION IN METASTATIC COLORECTAL CANCER
365
PRECLINICAL ANTITUMOR EFFICACY OF TAXOTERE RP56976 NSC 628503 A TAXOL ANALOG AND OF RP60475 NSC645008 A NEW B...
389
Авторські права

Інші видання - Показати все

Загальні терміни та фрази

Бібліографічна інформація